NCT03384316 2020-09-09Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerNational Institutes of Health Clinical Center (CC)Phase 1 Completed11 enrolled 18 charts